MP01-08 REZŪM WATER VAPOR THERAPY FOR LARGE VOLUME (≥80 ML) BENIGN PROSTATIC ENLARGEMENT: LARGE, MULTI-CENTER COHORT

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology I (MP01)1 Sep 2021MP01-08 REZŪM WATER VAPOR THERAPY FOR LARGE VOLUME (≥80 ML) BENIGN PROSTATIC ENLARGEMENT: LARGE, MULTI-CENTER COHORT Dean Elterman, Naeem Bhojani, Bilal Chughtai, and Kevin C. Zorn Dean EltermanDean Elterman More articles by this author , Naeem BhojaniNaeem Bhojani More articles by this author , Bilal ChughtaiBilal Chughtai More articles by this author , and Kevin C. ZornKevin C. Zorn More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001962.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Open or laser prostatectomy are the standard treatments for benign prostatic hyperplasia (BPH) of large volume prostates ≥80 mL. Rezūm is a minimally invasive procedure to ablate benign prostatic tissue. Herein, we report the prospective, multi-center results of the largest cohort of prostates ≥80 mL treated with Rezum. METHODS: A prospective registry was established for Rezūm therapy in Canada (2019) at two high-volume centers. All patients had baseline medical and BPH history documented along with uroflowmetry (Qmax and PVR), and validated questionnaires (IPSS, IPSS QoL, BPHII, IIEF-15, MSHQ-EjD function and bother). RESULTS: 83 patients (mean age 68.7 years) with prostate size ≥80 ml were treated with Rezūm from April 2019 to Dec 2020. The average prostate volume was 104.6 ml (range 80-160 ml) and 65% had a median lobe. 21 patients had prior episode of urinary retention. Mean number of injections was 13.6 (range 8-28). Mean duration of procedure was 5.9 minutes (range 2.5-14). Mean duration of post-procedure catheterization was 11.8 days. IPSS reduced from a baseline score of 20.9 by 24.3% (15.8), 56.7% (9), 59.1% (8.4) at 1, 3, 12 months respectively. IPSS QoL score improved from a baseline of 4.2 to 1.8 (-56%) at 3 months and 1.4 (-70%) at 12 months. Qmax improves from a baseline of 9.2 ml/s up to 14.3 ml/s (55%) at 3 months. BPHII improved from a baseline of 6.4 to 2.8 (-57%) at 3 months and 1.8 (-71%) at 12 months. IIEF showed no significant change from 52 at baseline to 57 at 12 months. Similarly, no changes in MSHQ function (10.3 to 10.1 at 12 months) or bother (1.4 to 1.3 at 12 months). No Clavien-Dindo events ≥ grade III occurred. CONCLUSIONS: Rezum therapy is safe, effective, quick, out-patient procedure in prostate glands ≥80 ml with similar outcomes to prostates <80 mL. Source of Funding: N/A © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e3-e3 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Dean Elterman More articles by this author Naeem Bhojani More articles by this author Bilal Chughtai More articles by this author Kevin C. Zorn More articles by this author Expand All Advertisement Loading ...